Trade Insulet Corporation - PODD CFD

About Insulet Corporation

Insulet Corporation is primarily engaged in the development, manufacture and sale of its proprietary Omnipod System, a continuous insulin delivery system for people with insulin-dependent diabetes. The Omnipod System includes the Omnipod Insulin Management System (Omnipod), the Omnipod DASHTM Insulin Management System (Omnipod DASH) and its digital mobile Omnipod platform. The Omnipod System features two devices: a small, lightweight, self-adhesive disposable tubeless Omnipod device (Pod) and a Personal Diabetes Manager (PDM). Users has to fill the Pod with insulin and wear directly on the body. It can be worn in multiple locations, including the abdomen, hip, back of upper arm, upper thigh or lower back. The Pod delivers precise, personalized doses of insulin into the body through a small flexible tube, cannula. PDM is a wireless, handheld device that programs the Pod with the user’s personalized insulin-delivery instructions and wirelessly monitors the Pod’s operation.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Insulet Corporation revenues increased 21% to $1.1B. Net income increased from $6.8M to $16.8M. Revenues reflect Omnipod System segment increase of 24% to $651.5M, International Omnipod segment increase of 17% to $359.9M, United States segment increase of 24% to $738.9M, All Other segment increase of 17% to $359.9M. Net income benefited from IE on Capital Financing decrease of 13% to $36.7M (expense).

Equity composition

Common Stock, $.001 Par, 03/12, 100M auth., 45,670,320 issd. Insiders own 0.45%. IPO: 5/07, 7.7M shs.@ $15 per share by JPMorgan, Merrill Lynch & Co., Thomas Weisel Partners LLC and Leerink Swann & Company. PO:11/07, 4.9M shs. @ $23.25 per share by JP Morgan and Merrill Lynch.